National Prescription Opiate
This MDL, centralized in the Northern District of Ohio in 2017, consolidates claims by thousands of cities, counties, states, tribes, hospitals, and third-party payors alleging that opioid manufacturers, distributors, and pharmacy chains fueled the opioid crisis through deceptive marketing of prescription opioids and inadequate controls on suspicious order volumes. Over the following years, the litigation produced a sequence of global settlements now totaling more than $50 billion: the three largest pharmaceutical distributors agreeing to pay up to $21 billion over 18 years, a leading opioid manufacturer and its corporate parent agreeing to pay up to $5 billion, additional settlements with other manufacturers, and more than $13 billion from major pharmacy chains resolving claims that they contributed to the epidemic through dispensing practices. Despite that scale of resolution, the docket carries 2,907 pending actions.
What drives the substantial remaining action count is the sheer scale and diversity of the original plaintiff population relative to the settlement classes that resolved the bulk of claims: thousands of individual government entities, tribes, hospital systems, and payors each had to decide whether to participate in the negotiated settlement structures, and a meaningful number either opted out, filed after key settlement deadlines, or hold claims that fall outside the settlements' defined scope, keeping their individual actions active in the MDL. Resolution for those remaining plaintiffs now benefits from an extensively developed liability and damages record built through years of litigation and negotiation across the earlier global settlements, even though each remaining plaintiff's specific claim still requires its own resolution.
For anyone tracking how the largest public-nuisance and abatement-based mass litigation in the federal system has unfolded, this docket demonstrates that even a series of unprecedented global settlements does not fully close out an MDL of this scale, since thousands of distinct institutional plaintiffs make individualized participation decisions. Criterica Intelligence's platform tracks this large-docket dynamic, extensive settlement activity alongside a persistently large remaining action count, as its own resolution pattern distinct from dockets that close out entirely once a global settlement is reached.
That opioid manufacturers, distributors, and pharmacy chains fueled the opioid crisis through deceptive marketing of prescription opioids and inadequate controls on suspicious order volumes, harming cities, counties, states, tribes, hospitals, and payors.
More than $50 billion in total value, including up to $21 billion from the three largest distributors, up to $5 billion from a leading manufacturer and its parent, and more than $13 billion from major pharmacy chains.
Thousands of distinct government entities, tribes, hospital systems, and payors each made individual decisions about whether to participate in the settlement structures, and many either opted out, filed later, or hold claims outside the settlements' scope.
That even unprecedented global settlements do not fully close out an MDL when the original plaintiff population numbers in the thousands, since individual institutional participation decisions keep a substantial remaining population active, a pattern Criterica Intelligence tracks distinctly from smaller dockets that close out entirely after settlement.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.